Results from trials of both Medtronic‘s (NYSE:MDT) and Edwards Lifesciences‘ (NYSE:EW) transcatheter aortic valve replacement systems exploring their use in low-risk patients indicated that the devices were as safe as open surgery, paving the way for possible new indications for TAVR technology. Data from the trials were presented over the weekend at the American College […]
Edwards Lifesciences gets in on Corvia, Mitralign
Edwards Lifesciences (NYSE:EW) said today that it made a pair of strategic bets on the structural heart space, paying $35 million for the right to acquire Corvia Medical and paying an unspecified amount for some of mitral valve repair device maker Mitralign‘s assets. Tewksbury, Mass.-based Corvia is developing an interatrial shunt to treat heart failure by […]
Edwards Lifesciences wins CE Mark for Pascal mitral repair device
Edwards Lifesciences (NYSE:EW) said late yesterday that it won CE Mark approval in the European Union for its Pascal transcatheter valve repair system intended to treat mitral regurgitation. The Pascal system is designed to reduce mitral regurgitation while maintaining native anatomy and features contoured, broad paddles to maximize coaptation of the mitral leaflets and a central […]
Edwards Lifesciences to acquire Casmed for $100m
Edwards Lifesciences (NYSE:EW) said today that it inked a deal to acquire CAS Medical System (NSDQ:CASM) and its non-invasive brain tissue oxygenation monitoring tech for approximately $100 million. Irvine, Calif.-based Edwards said that it will pay $2.45 per share of common stock of Branford, Conn.-based Casmed in the all-cash deal. Edwards said that it currently has a pending FDA […]
FDA labels Edwards Lifesciences’ recall of Swan Ganz thermodilution caths as Class I
The FDA has labeled a select recall of Edwards Lifesciences‘ (NYSE:EW) Swan-Ganz Thermodilution catheters over issues with the lumen assembly as Class I. Class I designations, the FDA’s most severe, are used when there is a reasonable probability that product use could cause serious adverse health consequences or death. The Irvine, Calif.-based company’s Swan-Ganz Thermodilution catheters function […]
Edwards Lifesciences posts Street-beating Q4, mixed-bag 2018 earnings
Edwards Lifesciences (NYSE:EW) today posted fourth quarter and full year 2018 earnings that topped earnings per share consensus on Wall Street, but missed on full-year sales expectations. The Irvine, Calif.-based company posted profits of $7 million, or 3¢ per share, on sales of $977.7 million for the three months ended December 31, seeing a swing to […]
Chinese national draws 27-month sentence in Medtronic, Edwards trade theft case
A Chinese national engineer who stole confidential trade secrets from Edwards Lifesciences (NYSE:EW) and ev3, formerly owned by Covidien and now a subsidiary of Medtronic (NYSE:MDT), has been sentenced to 27 months in federal prison, according to a posting from the U.S. Attorney’s Office for the Central District of California. Wenfeng Lu, 46, pleaded guilty last May […]
Edwards Lifesciences settlement with Boston Scientific lets Neovasc off the hook
Last week’s legal win for Boston Scientific (NYSE:BSX) in its years-long patent battle with Edwards Lifesciences (NYSE:EW) was also a win for Neovasc (NSDQ:NVCN), that company said today. As part of a settlement deal worked out between Irvine, Calif.-based Edwards and Marlborough, Mass.-based Boston Scientific, the Federal Court of Canada dismissed a lawsuit brought by Edwards against Boston, […]
Edwards Lifesciences pays $180m to bury the hatchet with Boston Scientific
Boston Scientific (NYSE:BSX) and Edwards Lifesciences (NYSE:EW) said today that they’re burying the hatchet, settling their worldwide patent war over cardiac valve and implant technology, with Edwards paying $180 million to end the dispute. “All pending cases or appeals in courts and patent offices between the two companies will be dismissed, and the parties will not litigate […]
10 of the best performing medical device stocks of 2018
Updated Jan. 8, 2019 Medical device company stocks are not looking as rosy as they did two months ago, but the medtech industry still appears to be resisting the overall downward trend in stock markets, according to a Medical Design & Outsourcinganalysis. More than half of the roughly 100 largest medical device companies in the world […]
FDA gives Edwards’ Sapien 3 Ultra TAVR the nod
Edwards Lifesciences (NYSE:EW) can now market its Sapien 3 Ultra transcatheter aortic valve replacement (TAVR) device in the United States. The FDA approved the device for severe, symptomatic aortic stenosis patients for whom open-heart surgery is considered an intermediate or greater risk, the Irvine, Calif.-based company said. For the Ultra, Edwards has added a taller […]
- 1
- 2
- 3
- …
- 40
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
YouTube